Erica N Evans

2.9k citations

44 papers · 1.2k indexed · h-index 19

Genetics top 5%
- Chronic Lymphocytic Leukemia Research 6
Hematology top 5%
Immunology top 10%
- Mast cells and histamine 9
Gastroenterology top 5%
Pathology and Forensic Medicine top 10%
Pulmonary and Respiratory Medicine
- Lung Cancer Treatments and Mutations 6
Oncology
- Cancer-related Molecular Pathways 5
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 5
Rheumatology
- Eosinophilic Disorders and Syndromes 5
Molecular Biology
- RNA Interference and Gene Delivery 4
- Cell death mechanisms and regulation 4

Co-authors: Daniel G. Tenen Hanna S. Radomska Juswinder Singh William Westlin Christoph Lengauer Mariana Nacht Alexandra K. Gardino Michael P. Sheets
Cited by: Genetics Hematology Immunology
Partner nations: United States United Kingdom Germany

In The Last Decade

Erica N Evans

43 papers receiving 1.2k citations

Peers

Countries citing papers authored by Erica N Evans

Since Specialization

Citations

This map shows the geographic impact of Erica N Evans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erica N Evans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erica N Evans more than expected).

Fields of papers citing papers by Erica N Evans

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erica N Evans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erica N Evans. The network helps show where Erica N Evans may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Erica N Evans, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Erica N Evans Line = papers co-authored together Erica N Evans links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Use of the microfluidic impedance red cell assay in sickle cell disease Akshay A Patwardhan,Ashwin Patel,Abhinav K Pasupuleti,Solomon Oshabaheebwa,Christopher A. Delianides,Zoe Sekyonda,Justin J Yoo,Jon Wade,Erica N Evans,Michael A. Suster,Pedram Mohseni,Umut A. Gürkan,Vivien Sheehan	2025	0
2	PU.1-c-Jun interaction is crucial for PU.1 function in myeloid development Xinhui Zhao,Boris Bartholdy,Yukiya Yamamoto,Erica N Evans,Meritxell Alberich-Jordà,Philipp B. Staber,Touati Benoukraf,Pu Zhang,Junyan Zhang,Bon Q. Trinh,John D. Crispino,Trang Hoang,Mahmoud A. Bassal,Daniel G. Tenen	2022	21
3	Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial Daniel J. DeAngelo,Deepti Radia,Tracy I. George,William A. Robinson,Albert Quiery,Mark W. Drummond,Prithviraj Bose,Elizabeth O. Hexner,Elliott F. Winton,Hans‐Peter Horny,Meera Tugnait,Oleg Schmidt-Kittler,Erica N Evans,Huimin Lin,Brenton G. Mar,Srđan Verstovšek,Michael W. Deininger,Jason Gotlib	2021	88
4	P2.03-44 BLU-667 Demonstrates Robust Activity in RET Fusion-Driven Intracranial Tumor Models Erica N Evans,Wei Hu,Feilin Cao,Klaus P. Hoeflich,Marion Dorsch	2019	14
5	Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis Johannes Lübke,Nicole Naumann,Sebastian Kluger,Juliana Schwaab,Georgia Metzgeroth,Erica N Evans,Alexandra K. Gardino,Christoph Lengauer,Wolf‐Karsten Hofmann,Alice Fabarius,Nicholas C.P. Cross,Andreas Reiter,Mohamad Jawhar	2019	33
6	An innovative medical student curriculum to address Human Papillomavirus vaccine hesitancy Abigail Schnaith,Britt Erickson,Erica N Evans,Caleb Vogt,Andrea Tinsay,Thomas Schmidt,Katelyn Tessier	2019	1
7	Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors Yemarshet K. Gebreyohannes,Agnieszka Woźniak,Madalina-Elena Zhai,Jasmien Wellens,Jasmien Cornillie,Ulla Vanleeuw,Erica N Evans,Alexandra K. Gardino,Christoph Lengauer,Maria Dêbiec‐Rychter,Raf Sciot,Patrick Schöffski	2018	57
8	MA26.03 Activity of Osimertinib and the Selective RET Inhibitor BLU-667 in an EGFR-Mutant Patient with Acquired RET Rearrangement Zofia Piotrowska,Hideko Isozaki,Jochen K. Lennerz,Subba R. Digumarthy,Justin F. Gainor,Nicolas Marcoux,Mandeep K. Banwait,Dora Dias‐Santagata,A. John Iafrate,Mari Mino–Kenudson,Rebecca J. Nagy,Richard B. Lanman,Erica N Evans,Corinne Clifford,Beni B. Wolf,Aaron N. Hata,Lecia V. Sequist	2018	1
9	Development and Content Validity of the Advanced Systemic Mastocytosis Symptom Assessment Form (ADVSM-SAF) Mazar,Erica N Evans,Fiona Taylor,Anil Patki,O Ojo,RE Lamoureux,H.‐P. Horny,Andreas Reiter,Jason Gotlib,Alan L. Shields	2016	2
10	Inhibitory Effects of Midostaurin and Blu-285 on Myeloid Progenitor Cells Derived from Patients with Multi-Mutated KIT D816V+ Advanced Systemic Mastocytosis Mohamad Jawhar,Nicole Naumann,Sebastian Kluger,Juliana Schwaab,Georgia Metzgeroth,Erica N Evans,Alexandra K. Gardino,Christoph Lengauer,Wolf‐Karsten Hofmann,Nicholas C.P. Cross,Alice Fabarius,Andreas Reiter	2016	2
11	A novel Bruton’s tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity Homare Eda,Loredana Santo,Diana Cirstea,Andrew J. Yee,Tyler A. Scullen,Neeharika Nemani,Yuko Mishima,Peter Waterman,Shirin Arastu‐Kapur,Erica N Evans,Juswinder Singh,Christopher J. Kirk,William Westlin,Noopur Raje	2014	37
12	Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans Erica N Evans,Richland Tester,Sharon Aslanian,Russell Karp,Michael P. Sheets,Matthew Labenski,Steven R. Witowski,Heather Lounsbury,Prasoon Chaturvedi,Hormoz Mazdiyasni,Zhendong Zhu,Mariana Nacht,Martin I. Freed,Russell C. Petter,Alex Dubrovskiy,Juswinder Singh,William Westlin	2013	171
13	Interleukin 2-inducible T cell kinase (ITK) facilitates efficient egress of HIV-1 by coordinating Gag distribution and actin organization Gillian M. Schiralli Lester,Hisashi Akiyama,Erica N Evans,Juswinder Singh,Suryaram Gummuluru,Andrew J. Henderson	2012	11
14	Abstract 1745: Translational medicine enables rapid early clinical development of AVL-292, a highly selective, orally available inhibitor of Bruton's tyrosine kinase, in a phase 1b clinical trial William Westlin,Kathryn Stiede,Heather Lounsbury,Steve Witowski,Bruce A. Silver,Martin I. Freed,Daruka Mahadevan,Jeff P. Sharman,Wael A. Harb,Russell C. Petter,Juswinder Singh,Erica N Evans	2012	4
15	Clinical Development of AVL-292; A Potent, Selective Covalent Btk Inhibitor for the Treatment of B Cell Malignancies, Erica N Evans,Richland Tester,Sharon Aslanian,Prasoon Chaturvedi,Hormoz Mazdiyasni,Sabine Ponader,Bethany Tesar,Michael P. Sheets,Mariana Nacht,Kathryn Stiede,Steve Witowski,Heather Lounsbury,Russell C. Petter,Jennifer R. Brown,Jan A. Burger,Juswinder Singh,William Westlin	2011	19
16	Does transforming growth factor-β1 predict for radiation-induced pneumonitis in patients treated for lung cancer? Erica N Evans,Zafer Koçak,S. Zhou,Daniel Kahn,Hsin-I Huang,Donna Hollis,K. Light,Mitchell S. Anscher,L.B. Marks	2006	35
17	Reaper-induced apoptosis in a vertebrate system Erica N Evans	1997	71
18	Crk is required for apoptosis in Xenopus egg extracts Erica N Evans	1997	43
19	Scedosporium prolificans, a multi-resistant fungus, from a U.K. AIDS patient Vicky Hopwood,Erica N Evans,Juliana Matthews,David W. Denning	1995	32
20	Characterization and Chromosomal Localization of ELANH2, the Gene Encoding Human Monocyte/Neutrophil Elastase Inhibitor Erica N Evans,Jessica Cooley,Eileen Remold‐O’Donnell	1995	21

About Erica N Evans

Erica N Evans is a scholar working on Hematology, Genetics and Immunology, having authored 44 papers that have together received 1.2k indexed citations. Recurring topics across this work include Mast cells and histamine (9 papers), Chronic Lymphocytic Leukemia Research (6 papers), Lung Cancer Treatments and Mutations (6 papers), Cancer-related Molecular Pathways (5 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), Eosinophilic Disorders and Syndromes (5 papers), RNA Interference and Gene Delivery (4 papers) and Cell death mechanisms and regulation (4 papers). The work is most often cited by research in Genetics (288 citations), Hematology (232 citations) and Immunology (379 citations). Erica N Evans has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Daniel G. Tenen, Hanna S. Radomska, Juswinder Singh, William Westlin, Christoph Lengauer, Mariana Nacht, Alexandra K. Gardino, Michael P. Sheets, Heather Lounsbury and Russell C. Petter.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact